Hyaluronic Acid
Evidence Fact Sheet
oral
Hyaluronic acid (oral/sodium hyaluronate) is a water-binding glycosaminoglycan studied as a beauty-from-within and joint-comfort supplement. RCT and meta-analysis evidence is strongest for skin hydration and elasticity; joint data come mainly from combination formulas, with honest non-significant outcomes reported.
Also known as: Sodium Hyaluronate · HA · Oral HA · Hyaluronan · Glycosaminoglycan (GAG) · GMP-Hyaluronan® · Injuv® · Mobilee® · Hyabest®
Overview
Hyaluronic acid (HA), supplied orally as sodium hyaluronate, is a glycosaminoglycan that binds water in the extracellular matrix of skin and connective tissue. Low-molecular-weight HA (<300 kDa) is associated with higher oral bioavailability, and research-context mechanisms include CD44/TLR4 signaling and support of endogenous HA and collagen synthesis; high-molecular-weight HA is thought to act more through barrier hydration and joint lubrication. Research doses are typically 80-240 mg/day (commonly standardized near 120 mg/day), with China and the EU recommending a maximum of 200 mg/day and ANVISA (Brazil) listing a maximum of 157.7 mg/day. Regulatory status: a US dietary-supplement ingredient (FDA reviewed GRN 491 with no questions; self-affirmed GRAS / NDI routes used) allowed structure/function claims only with the mandatory FDA disclaimer; in the EU fermentation-derived sodium hyaluronate was deemed not a novel food but has no authorized health claim; China approved it as a Novel Food ingredient (≤200 mg/day). Oral HA is distinct from injectable dermal fillers and intra-articular HA, which use different routes.
Mechanism of Action
Acts as a water-binding glycosaminoglycan that retains moisture in the extracellular matrix of skin and connective tissue · Low-molecular-weight (<300 kDa) oral HA is partially absorbed in the gut and tracer studies (animal) show distribution to skin and joint tissue, where it may serve as a substrate/signal for endogenous HA and collagen synthesis · Research-context: signaling through CD44 and TLR4 receptors and modulation of NF-kB / fibroblast activity has been proposed as a mechanism for skin and gut effects (mechanistic / preclinical evidence) · High-molecular-weight (>1000 kDa) HA is thought to act primarily through barrier hydration and joint lubrication rather than systemic absorption
Body systems: Skin & Connective Tissue · Musculoskeletal · Vision · Digestive & Gut
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Hyaluronic Acid is not characterized as a treatment for any disease.
Skin Hydration, Elasticity & Signs of Aging (Oral HA Monotherapy)
RCT supported- 150participants randomized
- 120 mg/dayeffective SH dose · 12 wk
- 1.8 MDasodium hyaluronate
In a 12-week randomized, double-blind, placebo-controlled trial, oral sodium hyaluronate at 120 mg/day significantly improved skin hydration and elasticity and reduced transepidermal water loss, sebum, and periorbital wrinkle depth versus placebo, with increased epidermal thickness and dermal density. The 60 mg/day dose showed similar but more modest effects. Several measures (colorimetric parameters, red areas, pore size, gloss) showed no change — an honest null embedded in a positive trial. The abstract reports outcomes directionally; numeric per-outcome effect sizes were not given in the abstract text.
Reported effect: 150 participants randomized to SH (1.8 MDa) at 60 mg/day, 120 mg/day, or placebo for 12 weeks; SH120 significantly enhanced hydration and elasticity and reduced TEWL, sebum, and periorbital wrinkle depth vs placebo (per-outcome numeric effect sizes not stated in abstract)
“A total of 150 participants were randomized to receive SH (1.8 MDa) at 60 mg/day (SH60), 120 mg/day (SH120), or placebo for 12 weeks. SH120 significantly enhanced skin hydration and elasticity, while reducing TEWL, sebum, and periorbital wrinkle depth versus placebo. It also improved skin structure by increasing epidermal thickness, dermal density, and NMF levels. SH60 showed similar but more modest effects. No changes were observed for colorimetric parameters, red areas, pore size, or gloss.”
Source: PMID 41422283 · Dolečková 2025 · Scientific Reports
Skin Hydration, Elasticity & Wrinkle Depth (Pooled Meta-Analysis)
Meta-analysis supported- 7oral-HA RCTs pooled
A meta-analysis of 7 randomized controlled trials of oral hyaluronic acid found statistically significant improvements in skin hydration, elasticity, and wrinkle depth. Honest negative: effects on skin firmness, wrinkle volume, and transepidermal water loss were NOT statistically significant, though a general trend of improvement was noted. The abstract did not report pooled effect sizes, confidence intervals, or p-values.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“A total of 7 randomized controlled trials (RCTs) on the use of oral HA as a supplement were identified. The meta-analysis revealed statistically significant improvements in skin hydration, elasticity, and wrinkle depth following oral HA supplementation. Although the effects of oral HA on skin firmness, wrinkle volume, and transepidermal water loss were not statistically significant, a general trend of improvement was observed in these parameters.”
Source: PMID 40911749 · Amin 2025 · Journal of Drugs in Dermatology
Joint Comfort in Mild Osteoarthritis (Combination Formula, Not Oral HA Alone)
RCT supported- 20.8 vs 10.6 mmK-VAS pain drop · p=0.0105
- −13.0 vs −5.5K-WOMAC total · p=0.0489
- 100participants enrolled
In a multicenter, randomized, double-blind, placebo-controlled trial (n=100) of a krill oil + astaxanthin + oral low-molecular-weight hyaluronic acid COMBINATION, the active group had a greater 12-week pain reduction on the Korean Visual Analog Scale (20.8 vs 10.6 mm, p=0.0105) and greater improvement in K-WOMAC total score (−13.0 vs −5.5, p=0.0489). Important caveat: this tests a multi-ingredient complex, so the benefit cannot be attributed to oral HA alone — consistent with the broader pattern that human joint data for oral HA come largely from combination products.
Reported effect: 12-week K-VAS pain reduction 20.8 ± 16.16 mm (active) vs 10.6 ± 17.58 (placebo), p = 0.0105; K-WOMAC total −13.0 ± 13.62 vs −5.5 ± 18.08, p = 0.0489 (combination of krill oil + astaxanthin + oral HA, n=100)
“mean reduction from baseline in the Korean Visual Analog Scale (K-VAS) at week 12 ... 20.8 ± 16.16 mm vs. 10.6 ± 17.58 ... p = 0.0105. K-WOMAC total score was also significantly improved in the FP-MD group at week 12 compared with placebo (-13.0 ± 13.62 vs. -5.5 ± 18.08, p = 0.0489).”
Source: PMID 37686801 · Hill 2023 · Nutrients
Dry Eye / Ocular Surface (Topical HA as Active Comparator)
Meta-analysis supported- 9 RCTs · 1295patients pooled
- MD 1.08 mmSchirmer · diquafosol vs HA
- MD 0.60 stear breakup time
A meta-analysis of 9 RCTs (1295 dry-eye patients) used topical hyaluronic acid as the active comparator against 3% diquafosol. Diquafosol showed modestly better tear-film outcomes (Schirmer's test mean difference 1.08 mm; tear breakup time 0.60 s; OSDI −3.59) but a higher rate of adverse events (odds ratio 1.71). This positions topical HA as a well-tolerated ocular-surface lubricant baseline rather than demonstrating an oral-HA effect; oral HA was not the tested route.
Reported effect: 9 RCTs, 1295 patients; vs HA, diquafosol Schirmer's test MD 1.08 mm (95% CI 0.41 to 1.76, p=0.002), tear breakup time MD 0.60 s (95% CI 0.20 to 0.99, p=0.003), OSDI MD −3.59 (95% CI −4.68 to −2.50, p<0.001); diquafosol higher adverse-event odds ratio 1.71 (95% CI 1.08 to 2.71, p=0.02)
“A total of nine RCTs involving 1295 patients with DED were included ... results of Schirmer's test (MD: 1.08 mm, 95% CI: 0.41 to 1.76, p = 0.002; I2 = 0%) ... tear breakup time (MD: 0.60 s, 95% CI: 0.20 to 0.99, p = 0.003; I2 = 63%) ... diquafosol was associated with a higher risk of overall adverse events as compared to HA (odds ratio: 1.71, 95% CI: 1.08 to 2.71, p = 0.02; I2 = 18%)”
Source: PMID 37162564 · Sun 2023 · Graefes Arch Clin Exp Ophthalmol
Dosage (research context · not a recommendation)
80-240 mg/day oral (commonly standardized at 120 mg/day); China and EU recommend a maximum of 200 mg/day. Low-molecular-weight HA (<300 kDa) is associated with higher oral bioavailability in research.
Regulatory Status · 4 Markets
- US · FDA
- Dietary supplement ingredient; FDA reviewed GRN 491 (Bioiberica rooster-comb-derived hyaluronic acid extract) with no questions (2014); fermented sodium hyaluronate is additionally marketed under self-affirmed GRAS / NDI notifications (e.g., Injuv, BioCell Collagen) with no FDA objection. Structure/function claims allowed with mandatory disclaimer: "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease."
- EU · EFSA
- Microbial-fermentation sodium hyaluronate was determined NOT to be a novel food in food supplements (European Commission Article 4 consultation, Ref. Ares(2023)1368064, 24 Feb 2023), so it is not on the EU Union novel-food list. NO authorized Article 13/14 health claim — skin-hydration and joint-maintenance claims received negative EFSA opinions; EU sales rely on ingredient/source statements only.
- CN · China
- Approved as Novel Food ingredient — sodium hyaluronate (NHC 2020 Announcement No. 9, issued 2021-01-07) expanded to conventional foods, ≤200 mg/day; also used in registered health foods.
- BR · ANVISA
- Oral hyaluronic acid is an authorized bioactive-substance constituent of food supplements under ANVISA IN no 28/2018, as amended by IN no 102/2021, listed with a maximum dose of 157.7 mg/day for adults aged 19+; no efficacy claim required.
Safety
Generally well tolerated; rare mild digestive discomfort. Short-term tolerance up to 960 mg/day in trials; 200 mg/day for 12 months without adverse effects (JFRL). No known significant drug interactions. China mandates an unsuitable-population label: infants/toddlers, pregnant and breastfeeding women. Pregnancy/lactation human data are insufficient — advise consulting a physician. Microbial-fermentation source is vegan-friendly and essentially allergen-free; rooster-comb (animal) source requires poultry-allergy and animal-origin labeling.
Related
Goals: skin-beauty · joint-bone
Lifestyles: menopause
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 41422283 · Dolečková 2025 · Scientific Reports — Skin Hydration, Elasticity & Signs of Aging (Oral HA Monotherapy)
- PMID 40911749 · Amin 2025 · Journal of Drugs in Dermatology — Skin Hydration, Elasticity & Wrinkle Depth (Pooled Meta-Analysis)
- PMID 37686801 · Hill 2023 · Nutrients — Joint Comfort in Mild Osteoarthritis (Combination Formula, Not Oral HA Alone)
- PMID 37162564 · Sun 2023 · Graefes Arch Clin Exp Ophthalmol — Dry Eye / Ocular Surface (Topical HA as Active Comparator)
Frequently Asked Questions
1. What dose of oral hyaluronic acid is used in research?
Research-context oral doses are typically 80-240 mg/day, commonly standardized near 120 mg/day. China and the EU recommend a maximum of 200 mg/day, and ANVISA in Brazil lists a maximum of 157.7 mg/day for adults. Low-molecular-weight HA (<300 kDa) is associated with higher oral bioavailability. This is an evidence summary, not dosing guidance — consult a qualified professional for personal use.
2. Does oral hyaluronic acid actually improve skin?
It is the most consistent research area. A 12-week RCT in 150 adults found 120 mg/day sodium hyaluronate significantly improved hydration and elasticity and reduced wrinkle depth versus placebo (Dolečková 2025, PMID 41422283), and a meta-analysis of 7 RCTs reported significant gains in hydration, elasticity, and wrinkle depth (Amin 2025, PMID 40911749). Honest caveat: in that meta-analysis, firmness, wrinkle volume, and transepidermal water loss were not statistically significant.
3. Is oral hyaluronic acid proven for joint pain?
The human evidence is largely from combination formulas, not oral HA alone. In a 100-participant RCT, a krill oil + astaxanthin + oral HA complex reduced K-VAS pain more than placebo (20.8 vs 10.6 mm, p=0.0105) and improved K-WOMAC total score (−13.0 vs −5.5, p=0.0489) (Hill 2023, PMID 37686801). Because it is a multi-ingredient product, the effect cannot be attributed to HA by itself.
4. Is oral hyaluronic acid the same as fillers or eye drops?
No — these are different routes. Injectable dermal fillers and intra-articular joint injections deliver HA directly to tissue, and dry-eye products apply HA topically to the ocular surface (where a meta-analysis used it as the active comparator; Sun 2023, PMID 37162564). Oral HA is a swallowed supplement and its evidence base, summarized here for skin and combination joint formulas, is separate from those medical routes.
5. What is the regulatory status of hyaluronic acid supplements?
In the US it is a dietary-supplement ingredient (FDA reviewed GRN 491 with no questions; self-affirmed GRAS / NDI routes are also used), allowing structure/function claims only with the mandatory FDA disclaimer. In the EU, fermentation-derived sodium hyaluronate was deemed not a novel food but carries no authorized health claim. China approved it as a Novel Food ingredient at ≤200 mg/day. None of these constitute approval to treat, cure, or prevent disease.
Last evidence review: 2026-06-13